Research from the Finlay/Gardiner labs has revealed a central role for cellular metabolism in the control of key immune cell functions [Finlay et al, 2012] and that glycolytic reprogramming of NK cells is essential for optimal NK cell effector function [Donnelly et al, 2014]. The glycolytic enzyme variant PKM2 is important in mediating glycolytic metabolism in cancer cells but recent data from Dr. McVicar’s lab show PKM2 in macrophages also links glycolytic metabolism and immune function. My central research question is to test the hypothesis that PKM2 is important in controlling NK cell metabolism and function.